DelMar Pharmaceuticals
Sep 12, 2017
Idera’s Phase I Data; DelMar Initiates Trial; Novartis’ study; Humira gets EC approval
Idera Pharmaceuticals Present Positive Phase I Data for their Drug candidate IMO-2125 Idera Pharmaceuticals announced final results from the dose-selection phase of an ongoing Phase 1/2 trial investigating IMO-2125 in combination with ipilimumab (Yervoy). The combination dose-selection phase included 18 patients, al...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
